Zynex (NASDAQ:ZYXI) Rating Lowered to Neutral at LADENBURG THALM/SH SH

Zynex (NASDAQ:ZYXI) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday, Marketbeat reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Zynex in a research report on Friday, December 6th.

Zynex Price Performance

Shares of NASDAQ:ZYXI opened at $2.90 on Wednesday. The company has a market capitalization of $92.35 million, a P/E ratio of 19.33 and a beta of 0.81. Zynex has a fifty-two week low of $2.77 and a fifty-two week high of $13.19. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company’s 50-day moving average is $7.52 and its 200 day moving average is $7.95.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). The company had revenue of $45.98 million during the quarter, compared to the consensus estimate of $53.65 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same quarter last year, the company posted $0.04 earnings per share. On average, equities research analysts forecast that Zynex will post 0.2 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the completion of the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 30,000 shares of company stock valued at $227,100 over the last quarter. 52.13% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zynex

Several large investors have recently bought and sold shares of the business. Hotchkis & Wiley Capital Management LLC grew its stake in shares of Zynex by 24.7% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares during the period. Geode Capital Management LLC lifted its position in shares of Zynex by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 443,020 shares of the company’s stock valued at $3,549,000 after buying an additional 17,511 shares in the last quarter. Royce & Associates LP lifted its position in shares of Zynex by 9.2% during the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock valued at $2,099,000 after buying an additional 21,781 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Zynex by 10.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock valued at $1,276,000 after buying an additional 14,820 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Zynex by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 137,362 shares of the company’s stock valued at $1,100,000 after buying an additional 3,800 shares in the last quarter. 29.68% of the stock is currently owned by institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.